ICCC - ImmuCell Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.9800
+0.0800 (+1.16%)
At close: 2:02PM EDT
Stock chart is not supported by your current browser
Previous Close6.9000
Open6.9700
Bid5.0000 x 100
Ask7.1100 x 200
Day's Range6.9700 - 7.2877
52 Week Range5.2600 - 9.2500
Volume2,572
Avg. Volume6,930
Market Cap38.252M
Beta2.46
PE Ratio (TTM)N/A
EPS (TTM)-0.1910
Earnings DateAug 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire13 days ago

    ImmuCell Announces Preliminary Sales Results for Second Quarter of 2018

    PORTLAND, Maine, July 10, 2018-- ImmuCell Corporation, a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity ...

  • GlobeNewswire28 days ago

    ImmuCell to Join Russell Microcap Index

    ImmuCell Corporation (ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, is set to join the Russell Microcap® Index at the conclusion of the Russell US Indexes annual reconstitution, effective after the U.S. market opens on June 25, 2018, according to a preliminary list of additions posted June 8, 2018. Russell US Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell US Indexes.

  • Should You Have ImmuCell Corporation’s (NASDAQ:ICCC) In Your Portfolio?
    Simply Wall St.last month

    Should You Have ImmuCell Corporation’s (NASDAQ:ICCC) In Your Portfolio?

    If you are a shareholder in ImmuCell Corporation’s (NASDAQ:ICCC), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ICCC earnings conference call or presentation 14-May-18 8:30pm GMT

    Q1 2018 ImmuCell Corp Earnings Call

  • ACCESSWIRE2 months ago

    Wired News - Stemline Therapeutics' SL-401 BPDCN Program Selected for Clinical Presentations at Upcoming EHA Congress

    LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want access to our free research report on Stemline Therapeutics, Inc. (NASDAQ: STML), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=STML as the Company's latest news hit the wire. On May 18, 2018, the Company announced that its SL-401 will be the subject of three clinical presentations, including an oral presentation on the pivotal blastic plasmacytoid dendritic cell neoplasm (BPDCN) program, at the upcoming 23rd Congress of the European Hematology Association (EHA), to be held from June 14-17, 2018, in Stockholm, Sweden. Updated data from the ongoing Phase-2 trial in chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF) will also be presented.

  • GlobeNewswire2 months ago

    ImmuCell Announces Financial Results for First Quarter of 2018

    PORTLAND, Maine, May 14, 2018-- ImmuCell Corporation, a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity ...

  • ACCESSWIRE2 months ago

    ImmuCell Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 14, 2018 / ImmuCell Corporation (NASDAQ: ICCC ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 14, 2018 at 4:30 PM Eastern Time. To ...

  • GlobeNewswire2 months ago

    ImmuCell to Announce Financial Results for First Quarter of 2018

    ImmuCell Corporation (ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, will report financial results for the first quarter of 2018 after the market closes on Monday, May 14, 2018. The Company has scheduled a conference call that same day, Monday, May 14, 2018, at 4:30 PM ET to review the results. ImmuCell Corporation's (ICCC) purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle.  ImmuCell has developed products that provide significant, immediate immunity to newborn dairy and beef livestock.  The Company is developing a novel treatment for mastitis, the most significant cause of economic loss to the dairy industry.  Press releases and other information about the Company are available at: http://www.immucell.com.

  • Who Are The Largest Shareholders In ImmuCell Corporation (NASDAQ:ICCC)?
    Simply Wall St.3 months ago

    Who Are The Largest Shareholders In ImmuCell Corporation (NASDAQ:ICCC)?

    In this analysis, my focus will be on developing a perspective on ImmuCell Corporation’s (NASDAQ:ICCC) latest ownership structure, a less discussed, but important factor. Ownership structure of a company hasRead More...

  • Where ImmuCell Corporation (NASDAQ:ICCC) Stands In Terms Of Earnings Growth Against Its Industry
    Simply Wall St.5 months ago

    Where ImmuCell Corporation (NASDAQ:ICCC) Stands In Terms Of Earnings Growth Against Its Industry

    For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find myRead More...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of ICCC earnings conference call or presentation 8-Feb-18 9:30pm GMT

    Q4 2017 ImmuCell Corp Earnings Call

  • ACCESSWIRE5 months ago

    ImmuCell Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 8, 2018 / ImmuCell Corporation (NASDAQ: ICCC ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 8, 2018 at 4:30 PM Eastern ...

  • ImmuCell Corp. :ICCC-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
    Capital Cube7 months ago

    ImmuCell Corp. :ICCC-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017

    Categories: Yahoo FinanceGet free summary analysis ImmuCell Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of ImmuCell Corp. – IDEXX Laboratories, Inc., Heska Corporation, Peregrine Pharmaceuticals, Inc., Aratana Therapeutics, Inc., Merck & Co., Inc., Kindred Biosciences, Inc., Abaxis, Inc., Riot Blockchain Inc, Zoetis, Inc. Class ... Read more (Read more...)

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of ICCC earnings conference call or presentation 13-Nov-17 9:30pm GMT

    Q3 2017 ImmuCell Corp Earnings Call

  • ImmuCell Corp. :ICCC-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
    Capital Cube9 months ago

    ImmuCell Corp. :ICCC-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017

    Categories: Yahoo FinanceGet free summary analysis ImmuCell Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of ImmuCell Corp. – Peregrine Pharmaceuticals, Inc. (PPHM-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 1.75 million, Net Earnings of USD -0.22 million. Gross ... Read more (Read more...)

  • Did ImmuCell Corporation (ICCC) Create Value For Investors Over The Past Year?
    Simply Wall St.10 months ago

    Did ImmuCell Corporation (ICCC) Create Value For Investors Over The Past Year?

    ImmuCell Corporation (NASDAQ:ICCC) delivered a less impressive 2.36% ROE over the past year, compared to the 15.86% return generated by its industry. ICCC’s results could indicate a relatively inefficient operationRead More...